MedTrace Logo

The Use of Medicinal Cannabinoids as Adjunctive Treatment for Medically Refractory Epilepsy

NCT02523183 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2020-01-18

No results posted yet for this study

Summary

Many families of children with medically refractory epilepsy are choosing to use medicinal cannabinoids (MCBD) as an adjunctive alternative treatment option. The safety, tolerability and efficacy of these products are not known. The primary objective of this study is to determine how the use of MCBD affects children with medically refractory epilepsy in an observational study. Measures of evaluation to be used will include: laboratory values, developmental measures, seizure diaries and serial electroencephalographic (EEG) recordings.

Conditions

  • Epilepsy, Unspecified, Refractory (Medically)

Interventions

DRUG

Medical Cannabis

Pediatric patients with medically refractory epilepsy and treated with medicinal cannabis.

Sponsors & Collaborators

  • Colorado Department of Public Health and Environment

    collaborator OTHER_GOV

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Kelly Knupp, MD · Assistant Professor of Pediatrics and Neurology

Eligibility

Min Age
1 Month
Max Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2020-10-31
Completion
2020-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02523183 on ClinicalTrials.gov